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CLINICAL SCIENCE
Prevalence of Novel Candidate Sjogren Syndrome
Autoantibodies in the Dry Eye Assessment and
Management (DREAM) Study
Vatinee Y. Bunya, MD,* Gui-Shuang Ying, PhD,* Maureen G. Maguire, PhD,* Eric Kuklinski, BA,†
Meng C. Lin, OD, PhD,‡ Ellen Peskin, MA, CCRP,* and Penny A. Asbell, MD,†§
the DREAM Study Research Group
Purpose: To evaluate the prevalence of novel candidate Sjogren
syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid
secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment
and Management (DREAM) cohort, a study evaluating the effective-
ness of omega-3 fatty acid supplements for the treatment of dry eye.
Methods: Participants underwent ocular surface examinations and
serological testing for traditional and novel SS autoantibodies. Dry
eye assessment and management participants were categorized into
the following 3 groups: 1) no history of SS or other autoimmune
diseases and negative traditional SS autoantibodies (n = 352); 2) no
history of SS but a history of other autoimmune diseases (n = 66);
and 3) those who met the 2012 American College of Rheumatology
SS classiﬁcation criteria (n = 52).
Results: Eleven percent had a history of SS, and 6% of those
without a history of SS most likely had undiagnosed SS. The SS
group had a higher prevalence of SP-1 autoantibodies than the group
without SS or other autoimmune diseases (33% vs. 19%; P = 0.02)
but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid
secretory protein autoantibodies (P = 0.33). Participants who were
positive for the traditional autoantibodies alone or positive for both
traditional and novel autoantibodies had the highest scores for
corneal (P = 0.002) and conjunctival staining (P , 0.001).
Conclusions: Data from this multicenter, prospective study
demonstrated that one of the novel candidate autoantibodies, SP-1,
is associated with underlying SS and that novel autoantibodies may
be associated with worse ocular surface disease. Future longitudinal
studies are needed to evaluate their utility in screening patients with
dry eye for SS.
Key Words: Sjogren syndrome, novel antibodies, dry eye
(Cornea 2018;37:1425–1430)
Sjogren syndrome (SS) is one of the most commonautoimmune diseases, affecting 2 to 4 million people in
the United States alone.1,2 SS is characterized by lymphocytic
inﬁltration of the exocrine glands, for example, lacrimal
glands and salivary glands, leading to symptoms of dry eye and
dry mouth. Patients with SS also have increased autoantibody
production and a higher risk of lymphoma.3 Signs and
symptoms of SS span the domains of ophthalmology, endocri-
nology, and rheumatology, and the diagnostic criteria are
complex.4–11 The diversity of signs and symptoms is a barrier
to early diagnosis, and many patients with SS are undiag-
nosed.4,12,13 Early detection of SS is important so that treat-
ments can be implemented to relieve symptoms and to enable
monitoring for systemic complications. In addition, patients
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who are administered biological agent treatment within the ﬁrst
5 years of disease onset may be more likely to respond to
treatment than those with delayed initiation of therapy.14–16
More speciﬁc and sensitive markers for SS are needed to
allow for earlier diagnosis and timely management of patients.
The traditional autoantibodies to SS-related antigen A (SSA/
Ro) and SS-related antigen B (SSB/La)1,17 are present in only
50% to 70% of patients with SS.17,18 In addition, because
traditional SS autoantibodies appear late in the course of
disease,19 patients with early SS are often negative for these
antibodies, thereby contributing to delays in diagnosis.
Recently, the novel autoantibodies salivary protein 1 (SP-
1), carbonic anhydrase 6 (CA-6), and parotid secretory protein
(PSP) have been identiﬁed as early markers of disease in
a mouse model of SS.20 However, there are limited data
regarding the expression and clinical signiﬁcance of these
antibodies in humans. These novel markers have been shown
to be present in some patients with dry eye with or without SS in
a few small studies21225, but studies examining the prevalence
of these antibodies in large, well-characterized cohorts are
needed to understand the clinical signiﬁcance of these autoanti-
bodies. In addition, information on how the expression of these
autoantibodies changes over time is needed.
The Dry Eye Assessment and Management (DREAM)
Study is a multicenter clinical trial funded by the National Eye
Institute, National Institutes of Health, to examine the efﬁcacy
and safety of an oral omega-3 fatty acid supplement for the
treatment of dry eye. Both dry eye patients with SS and those
without SS were enrolled in DREAM. The data from the
DREAM Study present a unique opportunity to assess the
prevalence of these novel candidate SS autoantibodies and any
associated ocular surface phenotypic features in a well-
characterized cohort of SS and non-SS dry eye patients.
METHODS
Subjects
The DREAM Study was a prospective, randomized,
double-masked, superiority clinical trial (clinicaltrials.gov:
NCT02128763) involving an active supplement group and
a placebo group. Participants were enrolled from 27 centers in
17 states throughout the United States. Institutional Review
Board/Ethics Committee approval was obtained. In addition,
the study adhered to the tenets of the Declaration of Helsinki
and was HIPAA compliant. After written informed consent was
obtained, participants who had at least 1 eye meeting the
DREAM criteria for dry eye were enrolled. Inclusion criteria
were age greater than or equal to 18 years; dry eye-related
ocular symptoms for at least 6 months before the screening
visit; and the use or desire to use artiﬁcial tears on average 2
times per day in the 2 weeks before the screening visit.
Participants also had to demonstrate the presence of at least 2 of
the 4 following signs in the same eye at the screening visit and
eligibility conﬁrmation visits: 1) conjunctival staining score$1
(out of a possible score of 6 per eye); 2) corneal ﬂuorescein
staining present $4 (out of a possible score of 15 per eye); 3)
tear breakup time #7 seconds; and 4) anesthetized Schirmer
test score $1 to #7 mm/5 min. In addition, participants had to
report symptoms of dry eye with an Ocular Surface Disease
Index (OSDI) score of at least 25 ($25 to#80) at the screening
visit and at least 21 ($21 to#80) at the baseline randomization
visit. Finally, participants had to demonstrate compliance with
taking placebo softgels as directed during a 2-week run-in
period ($90% taken, by pill count).
Major exclusion criteria were the following: the
presence of acute allergic conjunctivitis, infection, or inﬂam-
mation; history of ocular herpes keratitis; ocular surgery
within 6 months; history of previous LASIK or other corneal
surgery; use of glaucoma medication or history of ﬁltering
surgery for glaucoma; eyelid abnormalities or extensive
ocular surface scarring; anticoagulation therapy; contact lens
wear within 30 days of screening visit; current use of
eicosapentanoic acid/ docosahexanoic acid (EPA/DHA) sup-
plements greater than 1200 mg/day; and a history of allergy to
ingredients of supplements (active or placebo).
During the eligibility conﬁrmation visit, clinical coordi-
nators asked patients about their medical history, including
speciﬁc items on SS and rheumatoid arthritis. Participants
provided information regarding diagnoses of other autoimmune
diseases (rheumatoid arthritis, systemic lupus erythematosus,
ﬁbromyalgia, calcinosis, Raynaud phenomenon, esophageal
dysmotility, sclerodactyly, and telangiectasia), antiphospholipid
syndrome, Raynaud disease, scleroderma, graft-versus-host
disease, and sarcoidosis) when answering review of systems
questions. Patients provided a 4- to 10-mL blood sample that
was sent to a central laboratory for masked analysis of traditional
and novel SS autoantibodies (Sjo test; Immco Diagnostics, Inc,
Buffalo, NY). A standard enzyme-linked immunosorbent assay
for antibodies to SS antigens was used to detect immunoglobulin
G, immunoglobulin A, and immunoglobulin M antibodies in the
human serum extract reactive to recombinant SP-1, CA-6, and
PSP proteins expressed and puriﬁed from Escherichia coli.
Results were expressed in enzyme-linked immunosorbent assay
units per milliliter and were reported as positive or negative as
deﬁned by the manufacturer.25 Results of testing were made
available to the patient and the treating physician after they
exited the DREAM Study.
Designation of Sjogren Syndrome Status
We used the 2012 American College of Rheumatology
(ACR) criteria for SS10 as the basis for classifying DREAM
patients. The ACR criteria require that at least 2 of the
following 3 criteria be met: 1) positive for the traditional SS
antibodies [positive for SSA or positive for SSB or (positive
for rheumatoid factor and ANA $1:320)]; 2) ocular staining
score (OSS) from the cornea and conjunctiva of 3 or more in
the worse eye; and 3) labial salivary gland biopsy exhibiting
focal lymphocytic sialadenitis with a focus score of 1 focus/
4 mm2. Labial salivary gland biopsy results were not avail-
able for DREAM patients. The OSS was not used in the
DREAM study; however, for each eye, the corneal ﬂuores-
cein staining score (NEI scale; scores 0–15) was added to the
conjunctival lissamine green staining score (modiﬁed Oxford
scale; scores 0–6). We estimated that a total sum of corneal
and conjunctival staining of 3 or more was equivalent to an
OSS score of 3 or more. DREAM patients were classiﬁed as
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—1) group 1 (control group): those with an autoantibody
proﬁle that did not fulﬁll ACR criteria and without a reported
history of SS or other autoimmune diseases; 2) group 2: those
with an antibody proﬁle that did not meet ACR criteria,
without a reported history of SS but with a history of other
autoimmune diseases; and 3) group 3: those with an antibody
proﬁle that met ACR criteria and with a score of $3 on
DREAM ocular surface staining tests (SS group).
Data Analysis
The primary analysis compared the SS group (group 3)
and the control group (group 1) on the baseline characteristics
and prevalence of each of the novel autoantibodies using the
2-sample t test for means and the Fisher exact test for
proportions. Secondary analyses compared the autoimmune
disease group (group 2) and the control group for their
baseline characteristics and prevalence of antibodies.
To evaluate whether SS antibodies were associated with
more severe dry eye disease, signs and symptoms of dry eye
were compared among the following 4 groups of participants
based on their traditional and novel autoantibody status: 1)
positive for only the traditional autoantibodies; 2) positive for
only the novel autoantibodies; 3) positive for both traditional
and novel autoantibodies; and 4) negative for both traditional
and novel autoantibodies. All statistical analyses were
performed in SAS v9.4 (SAS Institute Inc, Cary, NC), and
P , 0.05 was considered statistically signiﬁcant.
RESULTS
Among 535 patients randomized to the DREAM study,
494 underwent antibody testing (Fig. 1). Antibody testing was
not performed when a licensed phlebotomist was unavailable
during the patient visit, the patient refused, or the appropriate
shipping materials were not available. Among those with
antibody testing, 52 (10.5%) patients met the ACR criteria for
inclusion in group 3 with SS, 66 (13.4%) reported an
autoimmune disease to qualify for group 2, and 352
(71.3%) reported no history of SS or autoimmune disease
and were included in the control group (group 1). Twenty-
four patients (4.9%) either reported a history of SS or had an
antibody proﬁle meeting ACR SS criteria but did not meet the
full ACR criteria and were considered indeterminate.
Baseline Characteristics
The baseline characteristics of the participants with SS
(group 3) compared with those without SS or other autoim-
mune diseases (group 1) are shown in Table 1. Participants
with SS were predominantly female (92%) and predominantly
white. There was no signiﬁcant difference in the mean OSDI
score between these 2 groups. However, the 4 key signs of dry
eye, tear breakup, Schirmer test, and corneal and conjunctival
staining, were signiﬁcantly worse in participants with SS than
in those without SS or other autoimmune diseases (all P #
0.02). Also, participants with SS used artiﬁcial tears (P =
0.004) or ointments (P = 0.01) more frequently than did those
without SS or those with other autoimmune diseases.
FIGURE 1. Flowchart of the analysis of DREAM study partic-
ipants regarding SS and autoantibody testing.
TABLE 1. Baseline Characteristics of DREAM Study
Participants With or Without SS
Baseline Characteristics
Group 1: No
SS and No
Other Autoimmune
Diseases* (n = 352)
Group
3: SS
(N = 52)† P
Age (yr): mean (SD) 58.8 (13.6) 56.6 (12.5) 0.91
Sex: male (%) 76 (22) 4 (8) 0.02
Race, n (%) 0.63
White 274 (78) 42 (81)
African American 39 (11) 4 (8)
Asian 13 (4) 1 (2)
American Indian or
Alaskan native
2 (1) 0 (0)
Mixed 4 (1) 2 (4)
Unknown 20 (6) 3 (6)
OSDI score: mean (SD) 41.4 (15.1) 42.8 (15.6) 0.55
Tear break-up time (s):
mean (SD) ‡
2.7 (1.4) 2.2 (1.1) 0.001
Schirmer test score (mm):
mean (SD)‡
8.4 (6.3) 6.3 (5.3) 0.02
Fluorescein staining of the
cornea: mean (SD) ‡
4.2 (2.9) 6.0 (3.6) 0.001
Lissamine green staining of
conjunctiva: mean (SD)‡
3.2 (1.4) 4.4 (1.5) ,0.0001
Frequency of using artiﬁcial
tears or gel use in the last
week, n (%)
0.004
0 80 (23) 5 (10)
1–2 times 160 (45) 19 (37)
3–4 times 65 (19) 11 (21)
5–10 times 32 (9) 11 (21)
Greater than 10 times 15 (4) 6 (12)
Regularly use lubricating
ointment (%)
29 (8) 10 (19) 0.01
Ever used steroid eye drops or
ointment (%)
74 (21) 17 (33) 0.06
*Group 1: participants without a history of SS or other autoimmune diseases and
negative in SSA, SSB, and not positive for both RF and ANA.
†Group 3: participants who would likely have met the 2012 American College of
Rheumatology SS classiﬁcation criteria based on serology and ocular surface staining.
‡From the worse eye of a speciﬁc ocular dry eye measurement.
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Novel Candidate SS Antibodies
Participants with SS had a higher prevalence (46%) of
expressing at least 1 novel autoantibody compared with those
without SS or other autoimmune diseases (31%; P = 0.02)
(Table 2). In particular, participants with SS had a higher
prevalence (33%) of SP-1 autoantibodies than those without
SS or other autoimmune diseases (19%; P = 0.02). However,
there was no signiﬁcant difference in the prevalence of CA-6
autoantibodies (21% vs. 15%; P = 0.31) or in PSP autoanti-
bodies (9.4% vs. 13.5%; P = 0.33).
Comparison by Antibody Groups
Among 4 groups based on testing results of the
traditional and novel candidate SS autoantibodies, demo-
graphic and ocular characteristics were similar (Table 3).
Participants who were positive for the traditional autoanti-
bodies alone or positive for both traditional and novel
autoantibodies had the highest scores for corneal staining (P
= 0.002) and conjunctival staining (P , 0.001) (Table 3).
Comparison of Non-SS Patients With or
Without Other Autoimmune Diseases
In a secondary analysis, the baseline characteristics and
the autoantibody status of 66 participants without SS but with
a history of another autoimmune disease (group 2) were
examined and compared with those without SS or other
autoimmune diseases (group 1) (see Supplemental Table 1,
Supplemental Digital Content 1, http://links.lww.com/ICO/A700,
and Supplemental Table 2, Supplemental Digital Content 2,
http://links.lww.com/ICO/A701). Approximately half (53%)
of the participants with another autoimmune disease
(group 2) reported having ongoing rheumatoid arthritis.
Participants in both of these groups (groups 1 and 2) were
of similar age and sex. There was a higher proportion of
African American patients in group 2 than in group 1 (21%
vs. 11%; P = 0.04). The mean OSDI score was similar be-
tween groups (P = 0.39). The mean score for each of the signs
of dry eye was worse in group 2 (those with other autoimmune
diseases) than in group 1 (no SS or other autoimmune
diseases), but none of the differences was statistically signif-
icant (all P $ 0.08) (see Supplemental Table 1, Supplemental
Digital Content 1, http://links.lww.com/ICO/A700). There
was a signiﬁcantly higher prevalence of autoantibodies
to CA-6 (25% vs. 15%; P = 0.047) and PSP (18% vs. 9%;
P = 0.049) in group 1 compared with group 2. However,
there was no difference in the prevalence of anti-SP-1
antibodies (group 1: 19% vs. group 2: 23%; P = 0.4) (see
Supplemental Table 2, Supplemental Digital Content 2,
http://links.lww.com/ICO/A701).
Correlation Between Traditional and Novel
SS Antibodies
Among all participants (groups 1–3) who underwent
testing for each autoantibody (n = 492), there was a weak
correlation (Pearson correlation coefﬁcient = 0.17; P = 0.0002)
between the number of participants who were traditional
autoantibody positive and the number who were novel
autoantibody positive (see Supplemental Table 3, Supplemen-
tal Digital Content 3, http://links.lww.com/ICO/A702).
DISCUSSION
In this study, we found that participants with SS had
a signiﬁcantly higher prevalence of SP-1 autoantibodies com-
pared with those without SS or other autoimmune diseases.
However, the prevalence of the novel autoantibodies in both SS
TABLE 2. Antibody Testing Results of DREAM Study
Participants With or Without SS
Baseline Antibodies
Group 1: No SS and No
Other Autoimmune
Diseases* (n = 352)
Group 3:
SS† (N =
52)
Fisher
Exact
P‡
Traditional SS antibodies:
SS-A (Ro) .25 EU/mL 0 (0.0%) 48 (92.3%)
SS-B (La) .25 EU/mL 0 (0.0%) 15 (28.9%)
Positive tests for SS-A
(Ro) and SS-B(La)
0 352 (100%) 2 (3.9%)
1 0 (0.0%) 37 (71.2%)
2 0 (0.0%) 13 (25.0%)
Anti-nuclear antibody
$1:320§
13 (3.7%) 23 (44.2%)
Rheumatoid factor: any
positive§
81 (23.1%) 32 (61.5%)
Positive tests for
traditional antibodies
0 258 (73.3%) 0 (0.0%)
1 94 (26.7%) 14 (26.9%)
2 0 (0.0%) 20 (38.5%)
3 0 (0.0%) 8 (15.4%)
4 0 (0.0%) 10 (19.2%)
Novel SS antibodies§
Salivary protein 1 (SP-
1): any positive
65 (18.5%) 17 (32.7%) 0.02
Carbonic anhydrase VI
(CA VI): any
positive
53 (15.1%) 11 (21.2%) 0.31
Parotid speciﬁc protein
(PSP): any positive
33 (9.4%) 7 (13.5%) 0.33
Positive in any novel
antibody
107 (30.5%) 24 (46.2%) 0.02
Positive tests for novel
antibodies
0.03k
0 244 (69.3%) 28 (53.9%)
1 66 (18.8%) 16 (30.8%)
2 38 (10.8%) 5 (9.6%)
3 3 (0.9%) 3 (5.8%)
*Group 1: participants without a history of SS or other autoimmune diseases and
negative in SSA, SSB, and not positive for both RF and ANA.
†Group 3: participants who would likely have met the 2012 American College of
Rheumatology SS classiﬁcation criteria based on serology and ocular surface staining.
‡No P values are provided for traditional SS antibodies because these values were
used to deﬁne the 2 comparison groups.
§One patient in the non-SS group had missing data for antibody testing.
kFor test of a linear trend.
EU, enzyme-linked immunosorbent assay units.
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and non-SS participants in our study differed from that of
previous reports.20–22,24–26 There are a few possible explanations
for the difference between the prevalence rates of the novel
autoantibodies in our study and those of previously published
studies. Factors such as differences in the classiﬁcation criteria
used to deﬁne SS, duration of disease, age, sex, and/or race and
ethnicity could account for the varying prevalence rates seen
across studies.
We also found that participants who were positive for
the traditional SS autoantibodies alone, or for both traditional
and novel autoantibodies, had worse corneal and conjunctival
staining than those who were not positive for any of these
autoantibodies. These novel autoantibodies may be a marker
of more severe ocular surface disease in those positive for
traditional SS antibodies. Future longitudinal studies are
needed to examine the time course for both traditional and
novel SS autoantibodies and to determine whether or not
ocular surface damage progresses more quickly among those
with speciﬁc subtypes of autoantibodies.
This study has certain limitations. First, the assignment of
case status of SS was based on a combination of traditional SS
antibody status and the ocular surface examination. However,
we did not have information on previous SS workups, and some
participants had never undergone lip biopsies. This could have
resulted in some misclassiﬁcation bias in that some patients in
the non-SS dry eye group may have had undiagnosed SS,
whereas some in the SS group may not have truly had SS. This
potential misclassiﬁcation would have diluted any real difference
in the prevalence of autoantibodies between both groups.
However, we found that the prevalence of traditional SS
autoantibodies in our participants with SS was similar to the
prevalence reported in well-characterized groups of patients with
SS, which supports our classiﬁcation of SS and non-SS
groups.20,27 In addition, we deﬁned our SS group as only those
who would have met the 2012 ACR classiﬁcation criteria for SS.
An additional limitation is that our SS group was
comprised of 52 participants. Therefore, our ﬁnding that there
was no signiﬁcant difference in novel autoantibody prevalence
between groups could be the result of a low statistical power to
detect a difference or a lack of true association. Future larger
studies would be helpful in conﬁrming our results. Another
limitation is that we did not have information about the duration
of SS. Because the novel candidate SS autoantibodies were
detected early in the course of disease in a mouse model, these
antibodies may be more likely to be present in patients with
early SS.20 It is possible that if many SS patients in our cohort
had longstanding disease then this would result in a lower
proportion of them to expressing these novel autoantibodies.
Longitudinal studies that assess the impact of the duration of SS
are needed. Finally, our cohort did not include any participants
TABLE 3. Comparison of Demographics, Dry Eye Symptoms, Signs, and Treatment Among SS Autoantibody Groups of
Participants in the DREAM Study*
Demographics
Negative for Traditional
and Novel SS Antibodies
(n = 214)
Positive for Only
Novel SS Antibodies
(n = 85)
Positive for Only
Traditional SS
Antibodies (n = 86)
Positive for
Traditional and
Novel SS Antibodies
(n = 63) P
Age (yr); mean (SD) 58.8 (13.3) 59.0 (12.7) 58.6 (12.7) 59.5 (15.3) 0.98
Sex: male (%) 45 (21.0) 16 (18.8) 17 (19.8) 8 (12.7) 0.53
Race, n (%) 0.03
White 169 (79.0) 67 (78.8) 54 (62.8) 53 (84.1)
African American 19 (8.9) 13 (15.3) 13 (15.1) 9 (14.3)
Asian 7 (3.3) 1 (1.2) 8 (9.3) 0 (0.0)
American Indian or Alaskan native 2 (0.9) 0 (0.0) 1 (1.2) 0 (0.0)
Mixed 3 (1.4) 2 (2.4) 2 (2.3) 1 (1.6)
Unknown 14 (6.5) 2 (2.4) 8 (9.3) 3 (3.9)
OSDI score: mean (SD) 42.1 (15.0) 42.7 (16.6) 38.8 (14.6) 42.6 (15.3) 0.3
Tear breakup time (s): mean (SD)† 2.8 (1.4) 2.7 (1.4) 2.6 (1.4) 2.3 (0.8) 0.09
Schirmer test score (mm): mean (SD)† 8.5 (6.5) 8.0 (6.0) 7.4 (5.7) 7.6 (6.3) 0.49
Staining of the cornea: mean (SD)† 4.1 (2.9) 4.3 (2.8) 4.9 (3.2) 5.7 (3.6) 0.002
Staining of conjunctiva: mean (SD)† 3.0 (1.4) 3.1 (1.5) 4.0 (1.5) 3.7 (1.6) ,0.001
Frequency of using artiﬁcial tears or gel use in
the last week, n (%)
0.7
0 49 (22.9) 18 (21.2) 20 (23.3) 11 (17.5)
1–2 times 83 (38.8) 43 (50.6) 34 (39.5) 30 (47.6)
3–4 times 47 (22.0) 12 (14.1) 20 (23.3) 14 (22.2)
5–10 times 23 (10.8) 10 (11.8) 6 (7.0) 5 (7.9)
Greater than 10 times 12 (5.6) 2 (2.4) 7 (7.0) 3 (4.8)
Regularly use lubricating ointment, n (%) 16 (7.5) 14 (16.5) 12 (14.0) 7 (11.1) 0.11
Ever used steroid eye drops or ointment, n (%) 36 (16.8) 23 (27.1) 23 (26.7) 19 (30.2) 0.047
*One participant without novel antibody results was excluded.
†From the worse eye of a speciﬁc ocular dry eye measurement.
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without dry eye. Future studies that include this subgroup would
be helpful in comparing the prevalence of the novel autoanti-
bodies in those with or without dry eye.
The traditional SS autoantibodies have limitations in
speciﬁcity and sensitivity; therefore, there is a need for better
biomarkers for SS. For example, recently, it was shown that
SSB antibodies, in the absence of SSA antibodies, were not
associated with key phenotypic features of SS,28 and as
a result, anti-SSB is not included in the latest set of
classiﬁcation criteria for SS.11 We found a weak correlation
between traditional SS antibody-positive results and novel
candidate SS-antibody positive results. Although the novel
candidate SS autoantibodies have shown promise in a mouse
model for SS, their meaning and clinical utility in humans
need to be studied further, including the sensitivity and
speciﬁcity of these antibodies for the early diagnosis of SS in
humans. In addition, the meaning of positivity of the different
isotypes of each novel autoantibody is unknown. Finally, it is
important to remember that these novel candidate SS auto-
antibodies are not currently part of any of the classiﬁcation
criteria sets for SS.9–11
We also found that approximately 11% of our dry eye
patient cohort reported having a history of SS, which is consistent
with previous reports.27 However, 6% of dry eye patients without
a history of SS most likely had undiagnosed SS based on the
2012 ACR criteria, underscoring the need for improved screening
methods and referrals for timely systemic evaluations for SS.
In conclusion, the DREAM clinical trial provides the
largest data set to date that allows for the examination of the
prevalence of novel candidate SS autoantibodies in dry eye
patients with or without SS. We found that dry eye patients with
SS had a signiﬁcantly higher prevalence of SP-1 autoantibodies
compared with those without SS or other autoimmune diseases.
In addition, among those with traditional SS autoantibodies, the
concomitant presence of the novel autoantibodies may be
a marker of more severe ocular surface disease. Longitudinal
data regarding autoantibody expression over time will be useful
in further examining the patterns of expression in SS and non-SS
dry eye patients and correlations with clinical disease.
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